French IT giant Capgemini initiates the sale of its U.S. federal subsidiary, Capgemini Government Solutions, attributing the move to restrictive oversight rules for classified contracts and a desire for strategic focus.
While small-cap stocks have broadly underperformed, recent insider buying activity points to potential value in select global companies. We examine three firms where leadership is putting their own capital to work.
The Austrian government has granted a two-year renewal for the Wolfsberg lithium mining license, with a final decision on production expected by end-2026 as lithium prices rebound strongly.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Alphabet's self-driving subsidiary Waymo is reportedly seeking a new funding round that would value the company at approximately $110 billion, drawing fresh attention to the tech giant's ambitious bets beyond its core advertising business and the evolving landscape of autonomous vehicle investment.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
The Hong Kong Monetary Authority (HKMA) is poised to grant its inaugural stablecoin issuer licenses in March, with approvals expected for only a select few firms. The move transitions the city's digital asset framework from sandbox testing to a formally regulated market, focusing on stringent risk controls and credible use cases.
Recent data shows the average Bitcoin held by U.S. spot ETFs is now worth less than its purchase price, following two consecutive weeks of major outflows that have deepened the cryptocurrency's downturn.
Despite a meteoric long-term rise, D-Wave Quantum's recent sharp decline highlights the extreme risks and towering valuations inherent in the speculative quantum computing sector. Investors face a critical decision.
With its core search business resilient, cloud division soaring, and new AI deals like the Apple partnership taking shape, Alphabet enters its February 4 earnings report on a strong note, though regulatory and valuation concerns linger.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
D-Wave Quantum Inc. announces the relocation of its headquarters and core R&D from Palo Alto, California, to Boca Raton, Florida, citing the state's business climate and partnership opportunities, in a move emblematic of a wider coastal tech migration.
Cardiac monitoring specialist iRhythm has finalized a significant corporate restructuring, creating a new parent company to serve as its publicly listed entity on Nasdaq. The move is seen as a strategic step to streamline governance and provide operational flexibility as the company expands its AI-driven health platform.
Shares of insulin pump maker Tandem Diabetes Care have plummeted over 80% in five years, trading near $20. A deep dive into valuation metrics suggests the stock may now be modestly undervalued, but significant risks and competitive pressures remain.
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.
Backed by regional sovereign wealth giants, Ruya Partners is launching a $400 million fund to address middle-market lending gaps in Saudi Arabia and the UAE, positioning itself as a key player in the Gulf's burgeoning private credit landscape.
